BACKGROUND: In the era of eculizumab, identifying patients with paroxysmal nocturnal hemoglobinuria who may benefit from allogeneic stem cell transplantation is challenging. DESIGN AND METHODS: We describe the characteristics and overall survival of 211 patients transplanted for paroxysmal nocturnal hemoglobinuria in 83 EBMT centers from 1978 to 2007. Next, we conducted a comparison with a cohort of 402 non-transplanted patients with paroxysmal nocturnal hemoglobinuria diagnosed between 1950 and 2005 in 92 French centers. We compared the occurrence of complications (i.e. thromboembolism and aplastic anemia) using either an individual or a stratum-matching procedure. RESULTS: After a median follow-up of 5 years, the 5-year overall survival rate ± standard error (%) was 68 ± 3 in the transplanted group (54 ± 7 in the case of thromboembolism, 69 ± 5 in the case of aplastic anemia without thromboembolism and 86 ± 6 in the case of recurrent hemolytic anemia without thromboembolism or aplastic anemia). Only thromboembolism as the indication for transplantation was associated with worse outcome (P=0.03). We identified 24 pairs of transplanted and non-transplanted patients with thromboembolism for the matched comparison, with worse overall survival for the transplanted patients (hazard ratio=10.0; 95% confidence interval, 1.3-78.1; P=0.007). This was confirmed by the global matching procedure (P=0.03). As regards aplastic anemia without thromboembolism, 30 pairs were identified for the matched comparison. It was not observed that transplanted patients had a significantly worse overall survival (hazard ratio=4.0; 95% confidence interval, 0.9-18.9; P=0.06). A global matching procedure was not feasible. CONCLUSIONS: Allogeneic stem cell transplantation is probably not a suitable treatment option for life-threatening thromboembolism in paroxysmal nocturnal hemoglobinuria.
BACKGROUND: In the era of eculizumab, identifying patients with paroxysmal nocturnal hemoglobinuria who may benefit from allogeneic stem cell transplantation is challenging. DESIGN AND METHODS: We describe the characteristics and overall survival of 211 patients transplanted for paroxysmal nocturnal hemoglobinuria in 83 EBMT centers from 1978 to 2007. Next, we conducted a comparison with a cohort of 402 non-transplanted patients with paroxysmal nocturnal hemoglobinuria diagnosed between 1950 and 2005 in 92 French centers. We compared the occurrence of complications (i.e. thromboembolism and aplastic anemia) using either an individual or a stratum-matching procedure. RESULTS: After a median follow-up of 5 years, the 5-year overall survival rate ± standard error (%) was 68 ± 3 in the transplanted group (54 ± 7 in the case of thromboembolism, 69 ± 5 in the case of aplastic anemia without thromboembolism and 86 ± 6 in the case of recurrent hemolytic anemia without thromboembolism or aplastic anemia). Only thromboembolism as the indication for transplantation was associated with worse outcome (P=0.03). We identified 24 pairs of transplanted and non-transplanted patients with thromboembolism for the matched comparison, with worse overall survival for the transplanted patients (hazard ratio=10.0; 95% confidence interval, 1.3-78.1; P=0.007). This was confirmed by the global matching procedure (P=0.03). As regards aplastic anemia without thromboembolism, 30 pairs were identified for the matched comparison. It was not observed that transplanted patients had a significantly worse overall survival (hazard ratio=4.0; 95% confidence interval, 0.9-18.9; P=0.06). A global matching procedure was not feasible. CONCLUSIONS: Allogeneic stem cell transplantation is probably not a suitable treatment option for life-threatening thromboembolism in paroxysmal nocturnal hemoglobinuria.
Authors: Nelson A Matos-Fernandez; Yasser R Abou Mourad; William Caceres; Mohamed A Kharfan-Dabaja Journal: Biol Blood Marrow Transplant Date: 2009-02-12 Impact factor: 5.742
Authors: Judith C W Marsh; Sarah E Ball; Jamie Cavenagh; Phil Darbyshire; Inderjeet Dokal; Edward C Gordon-Smith; Jane Keidan; Andrew Laurie; Anna Martin; Jane Mercieca; Sally B Killick; Rhona Stewart; John A L Yin Journal: Br J Haematol Date: 2009-08-10 Impact factor: 6.998
Authors: Hubert Schrezenmeier; Jakob R Passweg; Judith C W Marsh; Andrea Bacigalupo; Christopher N Bredeson; Eduardo Bullorsky; Bruce M Camitta; Richard E Champlin; Robert Peter Gale; Monika Fuhrer; John P Klein; Anna Locasciulli; Rosi Oneto; Antonius V M B Schattenberg; Gerard Socie; Mary Eapen Journal: Blood Date: 2007-05-02 Impact factor: 22.113
Authors: Régis Peffault de Latour; Jean Yves Mary; Célia Salanoubat; Louis Terriou; Gabriel Etienne; Mohamad Mohty; Sophie Roth; Sophie de Guibert; Sebastien Maury; Jean Yves Cahn; Gerard Socié Journal: Blood Date: 2008-06-05 Impact factor: 22.113
Authors: Peter Hillmen; Petra Muus; Ulrich Dührsen; Antonio M Risitano; Jörg Schubert; Lucio Luzzatto; Hubert Schrezenmeier; Jeffrey Szer; Robert A Brodsky; Anita Hill; Gerard Socié; Monica Bessler; Scott A Rollins; Leonard Bell; Russell P Rother; Neal S Young Journal: Blood Date: 2007-08-16 Impact factor: 22.113
Authors: Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen Journal: Blood Date: 2007-11-30 Impact factor: 22.113
Authors: Jason P Cooper; Rafic J Farah; Philip A Stevenson; Ted A Gooley; Rainer Storb; Bart L Scott Journal: Biol Blood Marrow Transplant Date: 2019-02-01 Impact factor: 5.742
Authors: Fahri Sahin; Olga Meltem Akay; Mesut Ayer; Mehmet Sinan Dal; Sehmus Ertop; Osman Ilhan; Volkan Karakus; Mehmet Ali Ozcan; Vildan Ozkocaman; Hayri Ozsan; Ozan Salim; Mahmut Tobu; Anil Tombak; Tulin Firatli Tuglular; Mehmet Yilmaz; Ali Unal; Mustafa Nuri Yenerel; Guray Saydam Journal: Am J Blood Res Date: 2016-08-05